PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

Study Overview
=================
Brief Summary
-----------------
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.

Official Title
-----------------
Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate

Conditions
-----------------
Sars-CoV2, Symptomatic Condition, Covid-19

Intervention / Treatment
-----------------
* Drug: Hydroxychloroquine Sulfate Regular dose
* Drug: Hydroxychloroquine Sulfate Loading Dose
* Drug: Chloroquine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptomatic patients: defined as fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute). Nasopharyngeal RT-PCR positive SARS-CoV-2 Age 20-50 years BMI 18-28 kg/m2 Informed consent Exclusion Criteria: O2 saturation by pulse-oximeter below 93% Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes Arrhythmias and/or history of arrythmia Psoriasis and/or history of psoriasis Neuropathy or myopathy and/or history of these Hypoglycemia and/or history of hypoglycemia Pre-existing hepatic disease Pre-existing renal disease Use of antacids within 1 week Use of antiobiotics within 1 week Pregnancy RT-PCR performed >7 days prior to enrollment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Prospective double blind randomized superiority clinical trial.
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: HCQ Regular dose<br>Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care | Drug: Hydroxychloroquine Sulfate Regular dose<br>* Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2<br>|
| Experimental: HCQ Loading dose<br>Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care | Drug: Hydroxychloroquine Sulfate Loading Dose<br>* Hydroxychloroquine administered as a loading dose only<br>|
| Active Comparator: CQ regular dose<br>Cholorquine 500 mg BID for 5 days plus standard of care | Drug: Chloroquine<br>* Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2<br>|
| Placebo Comparator: Placebo<br>Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine) | Drug: Placebo<br>* Standard of Care plus placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RT-PCR result | Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7 | 6th and 7th day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression of symptoms | Time to progression to next stage of SARS-CoV-2 disease severity index | 7 days | 
| Mortality | Death | 30 days |